Stretch growth targets in a market that was commoditizing underneath.

Andrew Aijian, PhD
Objective
Our Approach
Andrew Aijian brought his Senior Partner expertise in oncology biomarkers and pharma-services to the engagement, showcasing extensive depth across liquid biopsy, MRD, multi-omics, and the buyer side of pharma R&D services procurement. The engagement was structured as a six-week sprint into the long-range plan, including time to ground a growth strategy in primary research and converge on a small set of priorities the leadership team could allocate against.
Twenty-five interviews with senior biopharma decision-makers, weighted toward Director, Executive Director, and SVP-level stakeholders across discovery, translational, clinical trial, companion diagnostic, and real-world data functions, anchored the primary research. The interview mix spanned pre-commercial biotech through large pharma to surface where spend behavior diverged by company stage and where it converged. Stakeholders were probed on spend across the R&D tools and services biopharma deploys around drug development, on the trends reshaping where that spend was going, and on the vendor selection criteria that would govern which providers captured it.
A parallel competitive and category analysis assessed where the leading vendors sat against the criteria pharma was actually using to choose them, and located the segments where the client’s positioning was strongest, weakest, and most exposed to the commoditization pressure. The analysis covered seven therapeutic modalities, from established small molecules and antibodies through ADCs, cell and gene therapies, and emerging classes, because the answer to “where is biopharma R&D spend going” depends materially on which modalities are growing fastest and what tools they need.
The synthesis ran the candidate growth opportunities through a multi-factor scoring framework that triangulated market dynamics, competitive position, and portfolio fit. Eight investment categories were scored against the framework, ranging from areas where the client already led to adjacent categories the existing portfolio did not yet reach. Four priorities emerged, each with a distinct posture to build, partner, or invest, calibrated to the client’s starting position.
Outcome
The leadership team came out of the engagement with a structured set of growth priorities. Four opportunities emerged with a clear roadmap and time horizon, each reflective of where the category was heading and where the company was starting from. Together they composed a coherent growth thesis the long-range plan could be anchored on. The findings went one step further to demonstrate how the growth strategies interact with each other to create compound overall growth, rather than four standalone bets competing for the same dollar.
With the four priorities and the compounding lever identified, the leadership team had the framework it needed to underwrite the long-range plan: where to defend, where to invest, where to partner, and the order in which the bets would build on each other. The same scoring framework remained available as a reusable baseline, ready to absorb the next category dynamic, the next emerging modality, or the next competitor move as the biopharma market continued to shift.
Related Client Results







